HAP Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History

HAP Trading’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-96,480	Closed	-$2.36M	–	1962
2020 Q2	$2.36M	Buy	+96,480	New	+$1.9M	0.13%	133

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HAP Trading's RVNC Position: Q3 2020 in Review

HAP Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2020, closing a stake of 96,480 shares — an estimated $2.36M sold.

HAP Trading first reported a position in RVNC in Q2 2020 and held it in 1 quarter. The position peaked at $2.36M in Q2 2020. 153 funds tracked by Wall St. Rank hold RVNC as of Q3 2020.

HAP Trading reported no remaining Revance Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
HAP Trading sold 96,480 Revance Therapeutics, Inc. shares in Q3 2020, an estimated $2.36M.
HAP Trading first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
HAP Trading's Revance Therapeutics, Inc. position peaked at $2.36M in Q2 2020.
153 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2020.

Based on HAP Trading's 13F filing for Q3 2020, filed 13 Nov 2020.